echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Keytruda, Opdivo and Tecentriq will be reviewed by the FDA advisory committee this week

    Keytruda, Opdivo and Tecentriq will be reviewed by the FDA advisory committee this week

    • Last Update: 2021-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com



    According to the U.


    S.
    Food and Drug Administration (FDA)’s accelerated approval pathway, the fate of the three cancer immunotherapies will be determined this week after confirming trials have failed.


    The US FDA Oncology Drug Advisory Committee will review products approved under the breast, urinary tract tumors, gastric cancer and hepatocellular carcinoma pathways.


    "We are committed to ensuring the integrity of the accelerated approval program, which aims to bring safe and effective drugs to patients with unmet medical needs as soon as possible.


    In the past five months, these checkpoint inhibitor drugs have been withdrawn for other indications.


    AstraZeneca and Roche have also withdrawn the drug's oncology indications after failing confirmation trials.


    After AstraZeneca used Imfinizi for two weeks, Roche also withdrew Tecentriq's indication for bladder cancer.


    In late December 2020, BMS withdrew Opdivo as an indication for the treatment of small cell lung cancer (SCLC), and patients have progressed after platinum-based chemotherapy and at least one other treatment.


    The US FDA’s accelerated approval program allows patients with refractory cancers to use certain new therapies earlier.




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.